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Abstract
Background: Pentylenetetrazole (PTZ) has recently been found to ameliorate
cognitive impairment in rodent models of Down syndrome (DS). The mechanism
underlying PTZ’s therapeutic effect in DS is however not clear. Microarray profiling
has previously reported differential expression, both up- and down-regulation, of
genes in DS. Given this, transcriptomic data related to PTZ treatment, if available,
could be used to understand the drug’s therapeutic mechanism in DS. No such
mammalian data however exists. Nevertheless, a Drosophila model inspired by PTZ
induced kindling plasticity in rodents has recently been described. Microarray
profiling has shown PTZ’s downregulatory effect on gene expression in the fly heads.
Methods: In a comparative transcriptomics approach, I have analyzed the available
microarray data in order to identify potential therapeutic mechanism of PTZ in DS. In
the analysis, summary data of up- and down-regulated genes reported in human DS
studies and of down-regulated genes reported in the Drosophila model has been
used.
Results: I find that transcriptomic correlate of chronic PTZ in Drosophila counteracts
that of DS. Genes downregulated by PTZ significantly over-represent genes
upregulated in DS and under-represent genes downregulated in DS. Further, the
genes which are common in the downregulated and upregulated DS set show
enrichment for MAP kinase pathway.
Conclusion: My analysis suggests that downregulation of MAP kinase pathway may
mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase
pathway in DS supports this observation.
Background
Chronic treatment with nonconvulsive dosage of PTZ has recently been found to ame-
liorate cognitive impairment in rodent models of DS [1-4]. The mechanism underlying
PTZ’s potential therapeutic effect in DS is however unclear. Genome scale expression
analysis offers a promising approach to identify genes and pathways relevant in patho-
physiological and therapeutic mechanisms in complex CNS disorders [5]. Microarray
gene expression profiling has previously been reported in the analysis of control versus
DS astrocyte cell line and cerebrum or apical frontal pole [6], prefrontal cortex [7],
and neural progenitor cells [8]. However, transcriptomic analysis of effect of PTZ in
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any medium, provided the original work is properly cited.mammalian system has not been undertaken yet. This precludes understanding drug’s
potential mechanism using functional genomic data.
A Drosophila model inspired by rodent models of chronic PTZ induced kindling
plasticity has recently been developed [9]. In this model, PTZ causes a decreased speed
in startle-induced climbing in flies. Antiepileptic drugs, used in treating epilepsy and
other neurological and psychiatric disorders, suppress development of this behavioral
deficit. Microarray profiling has shown that PTZ exerts a downregulatory effect on
gene expression in fly heads. This effect has been found to mimic transcriptome and
proteome scale changes reported previously in human epilepsy patients and mamma-
lian models of epileptogenesis. Given the above, the fly model provides a systems level
framework for understanding potential disease and drug mechanisms [9]. In a com-
parative transcriptomics approach, I examine here if mining of the available fly [9] and
human [6-8] microarray data could uncover potential mechanism of PTZ action in DS.
Methods
Chronic PTZ regulated Drosophila genes, all downregulated, listed in Additional File
three of the previous report [9], were used in the analysis. Literature on relevant
microarray profiling in DS was searched in PubMed http://www.ncbi.nlm.nih.gov/
pubmed. For DS versus control microarrays, differentially expressed genes listed in
Supplementary Tables five a, five b, six a and six b of Mao et al.’s paper [6], Supple-
mentary Table three of Lockstone et al.’s paper [7], and Supplementary Data (≥1.5
fold) of Esposito et al.’s paper [8] was used. These human studies involved microarray
expression analysis of developing brain, adult brain, and neural progenitors, in that
order. Overlap between gene sets and pathway enrichment was examined using hyper-
geometric distribution probability in excel. The overlap was considered statistically sig-
nificant if the nominal p value was found to be less than 0.05. Human homologs (gene
symbols) of Drosophila genes were retrieved using Homologene option in FLIGHT
http://www.flight.licr.org/search/batch_homology.jsp. Gene IDs described in human
studies were converted to gene symbols using DAVID http://david.abcc.ncifcrf.gov/
summary.jsp, NCBI http://www.ncbi.nlm.nih.gov/unigene/ and SOURCE http://smd.
stanford.edu/cgi-bin/source/sourceBatchSearch. Genes were depicted in the KEGG
pathway for Homo sapiens http://www.genome.jp/kegg/tool/color_pathway.html.
Results
I first examined if PTZ regulated genes in Drosophila [9] counteract differentially
expressed genes in DS [6-8]. The three diverse DS studies reported differentially
expressed genes with insignificant overlap. Genes in DS studies were thus pooled
together for matching with human homologs of PTZ regulated genes (for gene lists,
see additional file 1). Strikingly, a significantly higher overlap was found between genes
downregulated by PTZ and genes upregulated in DS, and a significantly lower overlap
between downregulated genes in PTZ and DS sets (Figure 1). Enrichment for MAP
kinase pathway in DS upregulated genes has previously been reported [8]. In contrast,
downregulated genes in Drosophila, the only regulated genes in the PTZ model, have
been found to enrich MAP kinase pathway [9]. Thus, I next predicted that significant
overlap between PTZ downregulated and DS upregulated genes may result from coun-
teracting effect on MAP kinase signaling. Remarkably, the counteracting commonality
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MAP kinase pathway (Figure 2). Together, my transcriptomic analysis provided evi-
dence for the involvement of MAP kinase pathway in the mechanism of action of PTZ
in DS.
As the above enrichment analysis was biased for MAP kinase pathway due to the prior
hypothesis regarding its possible involvement, I next examined if evidence for this
pathway is further supported in an unbiased analysis. As in the above MAP kinase ana-
lysis, counteracting commonality genes between PTZ downregulated and DS upregu-
lated sets were compared against total DS upregulated genes. Six additional pathways
were found enriched in this analysis - Metabolic pathways (6 vs. 36 genes; p = 0.0008),
Focal adhesion (3 vs. 9 genes; p = 0.041), ErbB signaling pathway 3 vs. 7 genes; (p =
0.02), Arginine and proline metabolism (3 vs. 7 genes; p = 0.02), Natural killer cell
mediated cytotoxicity (3 vs. 5 genes; p = 0.007), and Vascular smooth muscle contrac-
tion (3 vs. 7 genes; p = 0.02). Interestingly, three of these pathways are directly con-
nected to MAP kinase pathway in the KEGG database. As such, this finding supported
the centrality of MAP kinase pathway in therapeutic action of PTZ in DS.
Figure 1 Venn diagram showing overlaps among PTZ and DS genes. Of the 716 total up- and down-
regulated genes in DS, 56 are common to the PTZ downregulated set. Of the 419 upregulated DS genes,
41 are common to the PTZ set. Of the 301 downregulated DS genes, 16 are common to the PTZ set. Note
significant enrichment in PTZ and DS total versus PTZ and DS upregulated (p = 0.011) and depletion in
PTZ and DS total versus PTZ and DS downregulated (p = 0.008).
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I have used two diverse set of summary data of transcriptomic profiling - related to
three separate human DS studies [6-8] and to the description of Drosophila PTZ
model [9] - to examine if potential mechanism(s) of drug action can be identified
through bioinformatics. The human studies reported differentially expressed genes in
DS brain in different context, namely, developing brain [6], adult brain [7], and neural
progenitors [8]. Not surprisingly, as mentioned above, no significant match was
observed between genes reported in these disparate studies. In contrast to human stu-
dies, the Drosophila data pertained to expression profiling of whole CNS from PTZ
treated animals. Despite potential confounding effects - arising out of tissue, species
and experimental diversity - in the reported data, I analyzed the data under the
assumption that genes in diverse human studies when combined together would cap-
ture a broader spectrum of expression changes in DS and hence be appropriate enough
for uncovering potential PTZ mechanism. Given this, it is striking that downregulation
of MAP kinase signaling pathway was identified as a potential therapeutic mechanism
by which PTZ may act in DS. This finding, notably, is supported by existing evidence
from diverse studies. For example, protein analysis of fetal brain cortex has previously
identified dysregulation of MAP kinase pathway related components in DS [10]. Also,
comparative genomics analysis has predicted perturbation in MAP kinase pathway in
DS [11]. Further, biochemical analysis has suggested a role of activated MAP kinase
signaling in brain pathogenesis in mouse DS model [12]. Besides, bioinformatic analysis
Figure 2 MAP kinase pathway showing counteracting commonality genes.O ft h e4 1 9D S
upregulated genes, 9 mapped on to the pathway. Of the 41 counteracting commonality genes, i.e., genes
common between PTZ downregulated and DS upregulated sets, 3 figured in the pathway map (BRAF,
PAK1 and PRKCA; represented by the three orange color boxes). Note significant enrichment of MAP kinase
pathway in counteracting commonality genes (p = 0.041).
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kinase pathway in the disease [13]. Biochemical, genomic and computational evidence
thus exist to support the plausibility of MAP kinase signaling as PTZ’s therapeutic tar-
get in DS.
Conclusion
Bioinformatic analysis of human and Drosophila transcriptome suggests that downre-
gulation of MAP kinase pathway may underlie therapeutic effect of pentylenetetrazole
in ameliorating cognitive impairment in DS. This warrants experimental validation in
rodent models of DS.
Additional material
Additional file 1: Differentially expressed genes reported in Drosophila model and DS studies. List of up-
and/or down-regulated genes reported by Mohammad et al., Esposito et al., Lockstone et al. and Mao et al.
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